GEHC GE HealthCare Technologies (GEHC) Insider Trading, Ownership & Congress Trades
Medical Devices · X-ray apparatus & tubes & related irradiation apparatus · CIK 0001932393
Cluster · 8 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
548
13F, latest reported quarter
What the filings say about GEHC
Insiders, 180 days
+$6.4M net bought
8 buyers
Congress, 1 year
0 bought · 2 sold
Latest: sale, 2026-03-25
GE HealthCare Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, GE HealthCare Technologies Inc. insiders bought a net $6.4M of stock across 23 Form 4 purchases and sales, with 8 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 69.6% of the 14,363 shares held after it.
- 7 other insiders bought within 30 days.
- 548 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lobo Kevin bought about $641.8K of GEHC on May 22, 2026; 7 other insiders bought within 30 days and 548 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,618 shares held after it.
- 7 other insiders bought within 30 days.
- 548 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hochman Rodney F bought about $100.4K of GEHC on May 12, 2026; 7 other insiders bought within 30 days and 548 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.3% of the 13,702 shares held after it.
- 7 other insiders bought within 30 days.
- 548 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Yang Watkin Phoebe L. bought about $63.0K of GEHC on May 8, 2026; 7 other insiders bought within 30 days and 548 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 23, 2023.
- The trade is 53.4% of the 151,207 shares held after it.
- 7 other insiders bought within 30 days.
- 548 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CULP H LAWRENCE JR bought about $5.0M of GEHC on May 6, 2026, the largest insider purchase at the company on our record; 7 other insiders bought within 30 days and 548 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 6.5% of the 15,330 shares held after it.
- 7 other insiders bought within 30 days.
- 548 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stromberg William J bought about $61.7K of GEHC on May 6, 2026; 7 other insiders bought within 30 days and 548 funds added in the latest 13F quarter.23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$6.4M over 180 days
more than 97% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
548 funds bought in last quarter
more than 96% of Medical Devices
Revenue
+4.8% year over year
below 66% of Medical Devices
Margin
10.1% net margin
more than 82% of Medical Devices
Buybacks
$100.0M repurchased, FY to 2026-03-31
more than 61% of Medical Devices
Short interest
4.1% of the float short (float per yahoo 2026-10-26) · 4.7 days to cover · settled 2026-09-30
more than 57% of Medical Devices
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch GEHC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GEHC: institutional holders (13F)
13F holdings, latest reported quarter
37,864,164 sh
$2.4B
37,467,843 sh
$2.4B
29,724,359 sh
$1.9B
20,861,566 sh
$1.3B
20,275,526 sh
$1.3B
Congress trades in GEHC
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-03-25 · disclosed 27 days later
$1,001 - $15,000
Sold 2026-03-23 · disclosed 2 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 20 days later
$1,001 - $15,000
Sold 2025-03-27 · disclosed 139 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GEHC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
GEHC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P Spin-Off ETF
$18.5M position · as of 2026-07-31
8.2%
iShares U.S. Medical Devices ETF
$136.4M position · as of 2026-06-30
4.5%
Global X HealthTech ETF
$1.0M position · as of 2026-05-31
4.2%
Hotchkis and Wiley Large Cap Fundamental Value Fund
$10.8M position · as of 2026-06-30
3.0%
Touchstone Strategic Trust-Touchstone Value Fund
$16.9M position · as of 2026-06-30
2.8%
Hotchkis and Wiley Global Value Fund
$1.0M position · as of 2026-06-30
2.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$18.6M
$19.6M
$5.7M
+36%
+22%
2024
$19.5M
$13.4M
$5.2M
+30%
+14%
2023
$24.5M
$29.8M
$9.1M
+28%
+1%
2022
$10.5M
$7.3M
$4.7M
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
8 insiders reported buying shares.
The record shows a net $6.4M bought by insiders over 180 days, 548 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GEHC financials
Revenue growth
+4.8%
XBRL, annual
Net margin
10.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.0B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM GEHC
| FY Dec 2025 | $20.6B |
| FY Dec 2024 | $19.7B |
| FY Dec 2023 | $19.6B |
| FY Dec 2022 | $18.3B |
| FY Dec 2021 | n/a |
| Mar 2026 | $5.1B |
| Dec 2025 | $5.7B |
| Sep 2025 | $5.1B |
| Jun 2025 | $5.0B |
| Mar 2025 | $4.8B |
| Dec 2024 | $5.3B |
| Sep 2024 | $4.9B |
| Jun 2024 | $4.8B |
At each fiscal year end
Single quarter
Net margin, TTM
+9.1%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM GEHC
| FY Dec 2025 | +10.1% |
| FY Dec 2024 | +10.1% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | +10.4% |
| FY Dec 2021 | n/a |
| Mar 2026 | +7.6% |
| Dec 2025 | +10.3% |
| Sep 2025 | +8.7% |
| Jun 2025 | +9.7% |
| Mar 2025 | +11.8% |
| Dec 2024 | +13.6% |
| Sep 2024 | +9.7% |
| Jun 2024 | +8.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM GEHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | $112.0M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $8.0M |
| Mar 2025 | $98.0M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | -$183.0M |
At each fiscal year end
Single quarter
Debt to equity
0.95x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity GEHC
| FY Dec 2025 | 0.96x |
| FY Dec 2024 | 1.06x |
| FY Dec 2023 | 1.32x |
| FY Dec 2022 | 0.88x |
| FY Dec 2021 | n/a |
| Mar 2026 | 0.95x |
| Dec 2025 | 0.96x |
| Sep 2025 | 1.03x |
| Jun 2025 | 1.06x |
| Mar 2025 | 0.95x |
| Dec 2024 | 1.06x |
| Sep 2024 | 1.24x |
| Jun 2024 | 1.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt GEHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+19.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity GEHC
| FY Dec 2025 | +22.2% |
| FY Dec 2024 | +25.6% |
| FY Dec 2023 | +19.0% |
| FY Dec 2022 | +14.7% |
| FY Dec 2021 | n/a |
| Mar 2026 | +19.2% |
| Dec 2025 | +22.2% |
| Sep 2025 | +24.2% |
| Jun 2025 | +25.6% |
| Mar 2025 | +26.3% |
| Dec 2024 | +25.6% |
| Sep 2024 | +21.7% |
| Jun 2024 | +21.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.4%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets GEHC
| FY Dec 2025 | +6.0% |
| FY Dec 2024 | +6.1% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +7.0% |
| FY Dec 2021 | n/a |
| Mar 2026 | +5.4% |
| Dec 2025 | +6.0% |
| Sep 2025 | +6.3% |
| Jun 2025 | +6.7% |
| Mar 2025 | +6.6% |
| Dec 2024 | +6.1% |
| Sep 2024 | +5.1% |
| Jun 2024 | +4.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.5%
operating income after a 23.4% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital GEHC
| FY Dec 2025 | +13.7% |
| FY Dec 2024 | +14.8% |
| FY Dec 2023 | +10.6% |
| FY Dec 2022 | +9.9% |
| FY Dec 2021 | n/a |
| Mar 2026 | +11.5% |
| Dec 2025 | +13.7% |
| Sep 2025 | +14.4% |
| Jun 2025 | +14.1% |
| Mar 2025 | +15.2% |
| Dec 2024 | +14.8% |
| Sep 2024 | +12.2% |
| Jun 2024 | +11.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.1%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed GEHC
| FY Dec 2025 | +10.8% |
| FY Dec 2024 | +11.2% |
| FY Dec 2023 | +11.1% |
| FY Dec 2022 | +12.4% |
| FY Dec 2021 | n/a |
| Mar 2026 | +10.1% |
| Dec 2025 | +10.8% |
| Sep 2025 | +10.7% |
| Jun 2025 | +11.2% |
| Mar 2025 | +11.6% |
| Dec 2024 | +11.2% |
| Sep 2024 | +10.1% |
| Jun 2024 | +10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
17.22x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing GEHC
| FY Dec 2025 | 17.99x |
| FY Dec 2024 | 18.06x |
| FY Dec 2023 | 25.60x |
| FY Dec 2022 | 13.83x |
| FY Dec 2021 | n/a |
| Mar 2026 | 17.03x |
| Dec 2025 | 17.99x |
| Sep 2025 | 15.52x |
| Jun 2025 | 15.18x |
| Mar 2025 | 16.99x |
| Dec 2024 | 18.06x |
| Sep 2024 | 25.78x |
| Jun 2024 | 22.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$40.6B
market value at close 2026-10-26 on 2026-04-22 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value GEHC
| FY Dec 2025 | $42.9B |
| FY Dec 2024 | $41.8B |
| FY Dec 2023 | $42.1B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | $40.3B |
| Dec 2025 | $42.9B |
| Sep 2025 | $40.6B |
| Jun 2025 | $40.5B |
| Mar 2025 | $43.2B |
| Dec 2024 | $41.8B |
| Sep 2024 | $49.6B |
| Jun 2024 | $42.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield GEHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -12%, PEG needs growth
PEG, trailing GEHC
| FY Dec 2025 | 3.39x |
| FY Dec 2024 | 0.42x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 3.39x |
| Sep 2025 | 0.47x |
| Jun 2025 | 0.36x |
| Mar 2025 | 0.44x |
| Dec 2024 | 0.42x |
| Sep 2024 | 3.09x |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $20.6B | $19.7B | $19.6B | $18.3B |
| Gross profit | $8.2B | $8.2B | $7.9B | $7.2B |
| Operating income | $2.8B | $2.6B | $2.4B | $2.5B |
| Net income | $2.1B | $2.0B | $1.6B | $1.9B |
| EPS (diluted) | 4.55 | 4.34 | 3.03 | 4.22 |
| Cash | $4.5B | $2.9B | $2.5B | $1.4B |
| Long-term debt | $9.5B | $7.4B | $8.4B | $8.2B |
| Buybacks | $200.0M | $0 | $0 | n/a |
| Dividends paid | $64.0M | $55.0M | $41.0M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
GEHC Stock Sonar score 6/7 axes
Find similar shapesCompareGEHC ranks highest on insider conviction (98th percentile) and profitability (75th), and lowest on financial health (20th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GEHC filings, in plain words
Are GE HealthCare Technologies insiders buying or selling GEHC?
In the 180 days to 2026-10-28, GE HealthCare Technologies insiders were net buyers, a net $6.4M across purchases and sales reported on Form 4, by 8 buyers.
Have members of Congress traded GEHC?
Yes. In the year to 2026-10-28, 0 House members disclosed buying GEHC and 2 House members disclosed selling it; the latest on record is a sale by Terri A. Sewell dated 2026-03-25.
Read the full summary
In the 180 days to 2026-10-28, GE HealthCare Technologies insiders were net buyers of GEHC, a net $6.4M across purchases and sales reported on Form 4 by 8 buyers. 8 insiders reported purchases in that window. In the year to 2026-10-28, 0 members of Congress disclosed buying GEHC and 2 members disclosed selling it; the latest on record is a sale by Terri A. Sewell dated 2026-03-25. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
